The Unique Accounting Challenges of the Cannabis Industry: Cash, 280E, and Inventory

Running the financial side of a cannabis business in 2026 is an exercise in navigating contradictions. You operate a state-legal business that the federal government still classifies as a Schedule I controlled substance. You collect sales tax on behalf of the state but cannot deduct ordinary business expenses on your federal return. You make millions in revenue but struggle to open a basic business bank account. You comply with meticulous state seed-to-sale tracking requirements while managing cash in volumes that would make a 1970s casino nervous.

These are not growing pains that will resolve with time. They are structural features of operating in the gap between state legalization and federal prohibition — a gap that the cannabis industry has lived in for over a decade and that shapes every financial decision from daily cash handling to long-term capital planning.

For accountants, CFOs, and business owners in the cannabis space, understanding these challenges is not optional. It is the difference between survival and catastrophic tax liability.

Section 280E: The Tax Code That Eats Margins

Section 280E of the Internal Revenue Code is the single most punitive financial burden facing cannabis businesses. Enacted in 1982 after a drug dealer successfully deducted business expenses on his tax return, 280E states that no deduction or credit shall be allowed for any amount paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances.

Because cannabis remains a Schedule I controlled substance under federal law, every cannabis business that touches the plant is subject to 280E. The practical impact is devastating.

How 280E Actually Works

In a normal business, you calculate taxable income by subtracting all ordinary and necessary business expenses from gross revenue. A retailer with $10 million in revenue and $8 million in expenses (including cost of goods sold, rent, payroll, marketing, utilities, and everything else) pays tax on $2 million.

Under 280E, a cannabis business can deduct only the Cost of Goods Sold (COGS) — the direct costs of acquiring or producing the product it sells. All other ordinary business expenses — rent, employee salaries (except those directly involved in production), marketing, insurance, professional services, utilities, security, and everything else — are not deductible.

Using the same $10 million revenue example: if COGS is $4 million and other expenses total $4 million, a normal business has $2 million in taxable income. A cannabis business under 280E has $6 million in taxable income because the $4 million in non-COGS expenses cannot be deducted.

At a combined federal and state tax rate of 30-40%, that difference turns a modestly profitable business into one hemorrhaging cash to the IRS. Effective tax rates for cannabis businesses under 280E commonly reach 60-80% of net income, and some businesses pay more in federal taxes than they earn in actual profit.

COGS Maximization: The Art of Allocation

Given the constraints of 280E, the most critical accounting strategy for cannabis businesses is maximizing what qualifies as COGS. This requires aggressive but defensible allocation of costs to production:

Cultivation Operations: Direct labor costs for employees who plant, grow, harvest, trim, and process cannabis are clearly COGS. Facilities costs (rent, utilities, depreciation) for cultivation spaces can be allocated to COGS based on square footage used for production versus administration.

Manufacturing/Processing: Costs of extraction, infusion, packaging, and testing that are directly tied to product creation qualify as COGS.

Inventory Absorption: Under IRS rules, cannabis businesses must use full absorption costing — allocating a portion of indirect production costs (facility overhead, quality control, production management) to inventory. This is one area where aggressive cost allocation can meaningfully reduce taxable income.

What Does NOT Qualify: Retail operations costs, sales staff salaries, marketing, general administrative expenses, and dispensary rent (as distinct from cultivation facility rent) cannot be included in COGS. For vertically integrated operators with both cultivation and retail, proper cost segregation between production and retail activities is essential.

The line between defensible COGS allocation and aggressive tax position is where most cannabis businesses need expert guidance. The IRS has increased audit activity in the cannabis sector, and 280E disputes are among the most common cannabis tax controversies.

The Rescheduling Question

The potential rescheduling of cannabis from Schedule I to Schedule III would eliminate the 280E burden for cannabis businesses — a change that would immediately improve operating margins by 20-30 percentage points for most operators. This single regulatory change represents the largest pending financial catalyst in the industry, which is why cannabis investors track rescheduling developments so closely. Our analysis of cannabis ETFs and investment vehicles examines how this potential change is being priced into public cannabis equities.

Cash Management: The Banking Problem

Despite years of incremental progress, the majority of cannabis businesses in 2026 still operate with restricted banking access. While more banks and credit unions now serve cannabis businesses than in the early legalization era — particularly in mature markets like Colorado, Oregon, and Washington — the fundamental federal prohibition creates ongoing friction.

The Current Banking Landscape

What Has Improved: Hundreds of financial institutions now serve cannabis businesses, typically through specialized compliance programs. Basic checking accounts, payroll processing, and ACH transfers are available to most licensed operators willing to pay premium banking fees (typically $2,000-5,000 per month for compliance-intensive accounts).

What Remains Difficult: Business loans from traditional lenders are still rare. Credit card processing for cannabis transactions remains largely unavailable, pushing dispensaries toward cash, debit-only systems, or cashless ATM workarounds of varying regulatory acceptability. Access to capital markets — public offerings, bond issuances, and institutional lending — remains constrained by federal prohibition.

What This Costs: Cannabis businesses pay 3-10x what comparable non-cannabis businesses pay for banking services. The compliance burden on partner financial institutions requires additional staff, reporting, and regulatory risk management that gets passed through as fees.

Cash Handling Realities

Despite improved banking access, cannabis businesses handle far more cash than any comparable retail industry. The accounting implications are significant:

Internal Controls: Robust cash handling procedures — dual custody, regular counts, reconciliation protocols, and armored transport — are not just best practices but regulatory requirements in most states. The cost of these controls adds 2-5% to operating expenses.

Theft and Shrinkage: Cash-heavy businesses face elevated theft risk from both external and internal sources. Loss prevention systems, including cameras, safes, and strict access controls, are essential and expensive.

Documentation: Every dollar of cash revenue must be meticulously documented through point-of-sale systems that integrate with state seed-to-sale tracking platforms. Discrepancies between reported sales and physical cash can trigger both state regulatory action and IRS scrutiny.

Cash Deposits: Banks that serve cannabis businesses impose strict documentation requirements for cash deposits. Each deposit must be accompanied by source documentation tying the cash to specific, compliant transactions. This creates a paperwork burden that can require dedicated staff.

Inventory Valuation: Where Seed-to-Sale Meets GAAP

Cannabis inventory accounting operates at the intersection of state regulatory requirements and Generally Accepted Accounting Principles (GAAP), and the two do not always align comfortably.

State Seed-to-Sale Requirements

Every legal cannabis market requires seed-to-sale tracking through platforms like Metrc, BioTrack, or Leaf Data Systems. These platforms track every plant, every gram of product, and every transaction from cultivation through final sale. The data is intended for regulatory compliance — ensuring product safety, preventing diversion, and enabling recalls — but it also generates an inventory record with accounting implications.

GAAP Inventory Accounting for Cannabis

Under GAAP, cannabis inventory must be valued using full absorption costing, which includes:

• Direct material costs (seeds, clones, nutrients, growing media)
• Direct labor costs (cultivation, harvest, processing staff)
• Manufacturing overhead (facility costs allocated to production)

The challenge is that cannabis inventory moves through multiple distinct stages — plant, harvested biomass, extracted oil, finished product — each with different cost bases and valuation methods. A vertically integrated operator that cultivates, extracts, manufactures, and retails must track cost through every transformation.

Biological Assets and IFRS

For cannabis companies reporting under International Financial Reporting Standards (IFRS) — primarily Canadian licensed producers — an additional complexity arises. IFRS requires biological assets (living cannabis plants) to be valued at fair value minus costs to sell, which can create dramatic revenue recognition events as plants grow and appreciate in theoretical value before they are harvested.

This accounting treatment produced the absurd-seeming headline revenue numbers that characterized the Canadian cannabis bubble of 2018-2019, when companies reported hundreds of millions in revenue that was substantially “unrealized gain on biological assets” rather than actual product sales. The subsequent write-downs when reality caught up with theoretical fair values contributed to the sector’s credibility crisis.

US cannabis companies reporting under GAAP are not required to use fair value for biological assets, making their financial statements generally more reflective of actual economic performance.

Practical Inventory Challenges

Spoilage and Waste: Cannabis is a perishable product with shelf life limitations. Inventory write-downs for expired, degraded, or unsalable product must be properly documented and valued.

Testing Failures: Product that fails state-mandated testing (for potency, pesticides, heavy metals, or microbial contamination) must be destroyed and written off. The cost of testing failures can be substantial, particularly for cultivation operations dealing with contamination issues.

Regulatory Holds: Product held for regulatory review or involved in compliance investigations must be valued and reported even though it cannot be sold. Accounting for inventory that may or may not become salable requires judgment and clear documentation.

Financial Reporting and Audit Considerations

Cannabis businesses face unique financial reporting challenges that affect both internal management and external stakeholder communication:

Audit Availability: Finding audit firms willing to serve cannabis companies has become easier but remains more difficult than in non-cannabis industries. The major accounting firms generally avoid plant-touching cannabis clients, leaving the market to mid-size and specialty firms. Audit fees for cannabis companies are typically 30-50% higher than for comparable non-cannabis businesses.

Revenue Recognition: Cannabis revenue recognition is generally straightforward — recognize at point of sale — but becomes complex for wholesale transactions with return provisions, volume discounts, or consignment arrangements.

Related-Party Transactions: The cannabis industry’s ownership structures — often involving multiple related entities, management companies, and real estate holding companies designed to manage 280E exposure — create related-party transaction issues that require careful disclosure.

Looking Forward

The accounting challenges facing the cannabis industry in 2026 are fundamentally driven by the gap between state legalization and federal prohibition. Federal rescheduling or descheduling would resolve the 280E burden. Federal banking legislation (the SAFE Banking Act or its successors) would normalize financial services access. Federal legalization would open standard capital markets.

Until those changes arrive, cannabis businesses and their financial professionals must continue operating in the most complex accounting environment in American business — maintaining dual compliance with state and federal requirements that actively contradict each other, managing cash in volumes that invite scrutiny, and paying effective tax rates that would bankrupt most industries.

The CFOs and controllers who thrive in cannabis are those who can hold the complexity without being paralyzed by it — making defensible decisions in a regulatory environment where the rules themselves are contradictory. It is the hardest accounting job in American industry, and the professionals who do it well deserve far more recognition than they receive.